QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy

Inclusion Criteria: 1. Patients with recurrent/metastatic cervical cancer who previously experienced failure of PD-1 blockade therapy; 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 3. Life expectancy ≥3 months; 4. At least one measurable lesion per RECIST v1.1: Non-lymph node lesion: Longest diameter ≥10 mm Lymph node lesion: Short-axis diameter ≥15 mm Note: Previously irradiated lesions must be outside radiation fields or demonstrate progression post-radiation. 5. Adequate organ function within 14 days prior to treatment: 1. Absolute neutrophil count (ANC) ≥1.0×10⁹/L 2. Hemoglobin ≥60 g/L 3. Platelet count ≥50×10⁹/L 4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3×ULN (≤5×ULN for hepatic metastasis) 5. Serum creatinine ≤2×ULN 6. Reproductive requirements: 1. Non-childbearing potential (surgically sterilized or postmenopausal) OR 2. Women of childbearing potential: Negative serum pregnancy test within 7 days prior to enrollment Commitment to use double-barrier contraception throughout the study and for 180 days post-treatment 7. Ability to comply with scheduled visits, treatment plans, and laboratory tests; 8. Voluntarily signed written informed consent. Exclusion Criteria: 1. Prior treatment with anti-PD-1/CTLA-4 bispecific antibodies; 2. Active autoimmune disease requiring systemic control with corticosteroids (≥10 mg/day prednisone equivalent) or immunosuppressants within 14 days prior to enrollment; 3. Clinically significant cardiovascular/cerebrovascular events within 6 months prior to treatment, including: 1. Acute myocardial infarction 2. Unstable angina 3. Cerebrovascular accident 4. Symptomatic arterial/venous thrombosis or ischemic cardiomyopathy 5. Clinically significant ventricular arrhythmias (sustained VT, VF, torsades de pointes) 6. NYHA Class III/IV heart failure 7. QTcF ≥480 ms or congenital long QT syndrome 8. LVEF \<50% or severe wall motion abnormality per echocardiography 9. Uncontrolled hypertension (SBP \>160 mmHg or DBP \>100 mmHg) 10. Other clinically significant arrhythmias (e.g., third-degree AV block); 4. Uncontrolled comorbidities potentially affecting protocol compliance: * Severe respiratory diseases (ILD, severe asthma) * Active infections: * HBV (HBsAg+ AND HBV-DNA \>500 IU/mL) * HCV (HCV-Ab+ AND HCV-RNA+) * HIV-Ab+ * Active TB or systemic infections requiring treatment ≤14 days * GI perforation/fistula ≤6 months (exceptions: resolved surgically) * Clinically significant bleeding ≤1 month (hematemesis, hemoptysis, etc.) * Active diverticulitis, abdominal abscess, or bowel obstruction; 5. Other malignancies within 3 years (excluding cured BCC, superficial bladder Ca, DCIS, or papillary thyroid Ca); 6. Known immunodeficiency disorders; 7. History of allogeneic hematopoietic stem cell or solid organ transplantation (excluding corneal grafts); 8. Systemic infections requiring IV antibiotics \>7 days within 2 weeks prior to treatment; 9. Administration of live attenuated vaccines within 4 weeks before/after treatment; 10. Pregnancy or lactation; 11. Investigator-assessed ineligibility; 12. Concurrent participation in other clinical trials.